TabsDetailsBasic DetailsDate Posted: Monday, January 16, 2012Status: CompleteMedical Product: angiotensin II receptor blocker (ARB), candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartanHealth Outcome(s): celiac diseaseDescription: Modular program-based one-time assessment of the risk of celiac disease associated with new use of angiotensin II receptor blockers (ARBs). Modular programs are adaptable standardized programs. Read More Deliverables (1)Mini-Sentinel Angiotensin II Receptor Blockers and Celiac DiseaseAdditional InformationAdditional DetailsFDA Center: CDERStudy Type: Modular ProgramAssessment Type: Exploratory AnalysesData Sources: Mini-Sentinel Distributed Dataset (MSDD)
